

isocode[®]

**Human Patient PBMC-Derived T Cell Guide
for IsoCode**

IsoCode
Reagent

IsoCode



Legal Notices


© 2018 IsoPlexis, Inc.. All rights reserved. Duplication and/or reproduction of all or any portion of this document without the express written consent of IsoPlexis, Inc., is strictly forbidden. Nothing contained herein shall constitute any warranty, express or implied, as to the performance of any products described herein. Any and all warranties applicable to any products are set forth in the applicable terms and conditions of sale accompanying the purchase of such product. IsoPlexis provides no warranty and hereby disclaims any and all warranties as to the use of any third party products or protocols described herein. The use of products described herein is subject to certain restrictions as set forth in the applicable terms and conditions of sale accompanying the purchase of such product. “IsoPlexis”, “Elevate Your Data”, “IsoLight”, “IsoCode”, “IsoSpeak” are trademarks of IsoPlexis, Inc.. All other trademarks are the property of their respective owners. All products and services described herein are intended FOR RESEARCH USE ONLY and NOT FOR USE IN DIAGNOSTIC PROCEDURES.

The use of IsoPlexis Product(s) in practicing the methods set forth herein has not been validated by IsoPlexis, and such non-validated use is NOT COVERED BY IsoPlexis STANDARD WARRANTY, AND IsoPlexis HEREBY DISCLAIMS ANY AND ALL WARRANTIES FOR SUCH USE.

Nothing in this document should be construed as altering, waiving or amending in any manner IsoPlexis, Inc., terms and conditions of sale for the IsoLight™ Automation Platform or the IsoCode and IsoSpeak consumables or software, including without limitation such terms and conditions relating to certain use restrictions, limited license, warranty and limitation of liability, and nothing in this document shall be deemed to be Documentation, as that term is set forth in such terms and conditions of sale. Nothing in this document shall be construed as any representation by IsoPlexis, Inc. that it currently or will at any time in the future offer or in any way support any application set forth herein.

Selected References:

Seo et al., *Journal of Clinical Oncology* 2018
 Ma et al., *Cancer Discovery* 2013



IsoCode Chip Pre-Chip Stimulation

- A.** 48-hour stimulation with bound αCD3 and soluble αCD28
 - 1)** 10 µg/mL plate bound αCD3 for 2 hours at 37°C
 - 2)** 4 µg/mL soluble αCD28 added with 1 million cells/mL

T cell Enrichment

- A.** Ficoll cells to ensure >80% viability
- B.** Enrich for CD4+ T cells via Miltenyi CD4+ T Cell Isolation Kit (see kit protocol)
- C.** Enrich for CD8+ T cells via Miltenyi CD8+ T Cell Isolation Kit (see kit protocol)

Enriching for CD4+ or CD8+ T cell population is required in order to detect cell subsets in required quantities on the IsoCode Chip

IsoCode Chip Staining Step

- A.** Add Stain A* to enriched CD4+ T cells
- B.** Add Stain B* to enriched CD8+ T cells

See 'IsoLight Manual' for additional stains and for exact volumes and cell concentrations

Loading onto the IsoLight

- A.** Add cells at 800,000 cells/mL to the IsoCode Chip and load onto the IsoLight

Wait for IsoCode Results

- A.** Review data after completion of 24 hour run